Exact Sciences (EXAS) Proxy Filing summary

Executive summary

• International business expanded significantly, with 18% revenue growth in 2025 and new offices in Tokyo, Munich, and Warsaw.

• Over 2 million patients worldwide have been served with Oncotype DX, supporting global cancer care.

• Plans to launch Cancerguard in the UAE, Saudi Arabia, Canada, and Japan within six months, and Cologuard in selected international markets by end of 2026.

• Integration with Abbott is expected to accelerate international growth due to their global health system reach.

ESG and sustainability initiatives

• Focus on reducing the global toll of cancer by expanding access to early detection and personalized treatment.

• Commitment to serving patients worldwide and supporting clinicians with regionally tailored solutions.

Risk oversight and compliance

• Initiated the CRANE Study in Japan to generate local evidence for regulatory progress and adoption of Cancerguard.